|1.||Pakola, Steve: 5 articles (08/2009 - 09/2002)|
|2.||Verhamme, Peter: 4 articles (07/2010 - 08/2009)|
|3.||Trese, Michael T: 3 articles (02/2011 - 10/2007)|
|4.||Stassen, Jean-Marie: 3 articles (07/2010 - 08/2009)|
|5.||Goldenberg, David T: 2 articles (02/2011 - 01/2009)|
|6.||de Smet, Marc D: 2 articles (10/2010 - 07/2009)|
|7.||Lijnen, H Roger: 2 articles (07/2010 - 08/2009)|
|8.||Gandorfer, Arnd: 2 articles (07/2009 - 02/2004)|
|9.||Kampik, Anselm: 2 articles (07/2009 - 02/2004)|
|10.||Dang, Loan: 2 articles (02/2009 - 10/2007)|
|1.||Vitreous Detachment (Posterior Vitreous Detachment)
02/01/2011 - "Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. "
01/01/2011 - "Safety of the anterior vitreous detachment induced by microplasmin, or pharmacologic vitreolysis to separate the posterior capsule from the anterior hyaloid."
10/01/2010 - "Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment."
09/01/2005 - "To investigate the safety of intravitreal microplasmin in rabbits and to confirm previous findings of posterior vitreous detachment (PVD). "
02/01/2004 - "Posterior vitreous detachment induced by microplasmin."
06/01/2012 - "The primary outcome was complete thrombolysis defined as >95% thrombus volume reduction at the end of the microplasmin infusion. "
04/01/2011 - "A novel human microplasmin fold: new perspective to thrombosis treatment."
11/01/2009 - "We investigated the safety and efficacy of intra-catheter microplasmin bolus administration for the restoration of catheter function in long-term venous access catheter thrombosis. "
11/01/2009 - "A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis."
02/01/2003 - "The effect of recombinant human microplasmin was studied in ischemic stroke models in mice and in an extracorporeal loop thrombosis model in rabbits. "
09/01/2002 - "It has been proposed that the novel thrombolytic microplasmin may be useful in the treatment of ischemic stroke. "
12/01/2009 - "Further studies are warranted to determine whether microplasmin is an effective therapeutic agent for ischemic stroke."
12/01/2009 - "We tested the tolerability of microplasmin in patients with acute ischemic stroke. "
12/01/2009 - "Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke."
08/01/2009 - "Administration of microplasmin has been found to neutralize alpha(2)-antiplasmin (alpha(2)-AP) activity, which has been associated with reduced infarct size in various preclinical models of stroke. "
|4.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
02/01/2008 - "The purpose of the present study was to examine the effects of microplasmin on behavioral performance and infarct volume after middle cerebral artery occlusion (MCAO) in rats. "
09/01/2004 - "Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice."
09/01/2002 - "The present study shows that microplasmin improves behavioral rating scores in the RSCEM when administered 60 minutes after embolization, at a dose that does not increase hemorrhages in the RLCEM. "
11/01/2009 - "No bleeding complications nor other adverse events were related to microplasmin. "
09/01/2002 - "The microplasmin dose of microplasmin that was statistically significant (4 mg/kg) was subsequently determined to be safe in the RLCEM because it did not increase the incidence of hemorrhages (56%) compared with vehicle-treated rabbits (63%), nor did it significantly alter hemorrhage volume, infarct rate, or infarct volume. "
|1.||Tissue Plasminogen Activator (Alteplase)
|9.||Conditioned Culture Media